Antimicrobial treatment of "complicated" intra-abdominal infections and the new IDSA guidelines ? a commentary and an alternative European approach according to clinical definitions
- PMID: 21486724
- PMCID: PMC3352208
- DOI: 10.1186/2047-783x-16-3-115
Antimicrobial treatment of "complicated" intra-abdominal infections and the new IDSA guidelines ? a commentary and an alternative European approach according to clinical definitions
Abstract
Recently, an update of the IDSA guidelines for the treatment of complicated intraabdominal infections has been published. No guideline can cater for all variations in ecology, antimicrobial resistance patterns, patient characteristics and presentation, health care and reimbursement systems in many different countries. In the short time the IDSA guidelines have been available, a number of practical clinical issues have been raised by physicians regarding interpretation of the guidelines. The main debatable issues of the new IDSA guidelines are described as follows: The authors of the IDSA guidelines present recommendations for the following subgroups of "complicated" IAI: community-acquired intra-abdominal infections of mild-to-moderate and high severity and health care-associated intra-abdominal infections (no general treatment recommendations, only information about antimicrobial therapy of specific resistant bacterial isolates). From a clinical point of view, "complicated" IAI are better differentiated into primary, secondary (community-acquired and postoperative) and tertiary peritonitis. Those are the clinical presentations of IAI as seen in the emergency room, the general ward and on ICU. Future antibiotic treatment studies of IAI would be more clinically relevant if they included patients in studies for the efficacy and safety of antibiotics for the treatment of the above mentioned forms of IAI, rather than conducting studies based on the vague term "complicated" intra-abdominal infections. - The new IDSA guidelines for the treatment of resistant bacteria fail to mention many of new available drugs, although clinical data for the treatment of "complicated IAI" with new substances exist. Furthermore, treatment recommendations for cIAI caused by VRE are not included. This group of diseases comprises enough patients (i.e. the entire group of postoperative and tertiary peritonitis, recurrent interventions in bile duct surgery or necrotizing pancreatitis) to provide specific recommendations for such antimicrobial treatment. - A panel of European colleagues from surgery, intensive care, clinical microbiology and infectious diseases has developed recommendations based on the above mentioned clinical entities with the aim of providing clear therapeutic recommendations for specific clinical diagnoses. An individual patient-centered approach for this very important group of diseases with a substantial morbidity and mortality is essential for optimal antimicrobial treatment.
Similar articles
-
[Antibiotic therapy of intra-abdominal infections in the era of multiresistance].Chirurg. 2016 Jan;87(1):26-33. doi: 10.1007/s00104-015-0106-9. Chirurg. 2016. PMID: 26577434 Review. German.
-
Essentials for selecting antimicrobial therapy for intra-abdominal infections.Drugs. 2012 Apr 16;72(6):e17-32. doi: 10.2165/11599800-000000000-00000. Drugs. 2012. PMID: 22480338 Free PMC article.
-
The 2018 Lebanese Society of Infectious Diseases and Clinical Microbiology Guidelines for the use of antimicrobial therapy in complicated intra-abdominal infections in the era of antimicrobial resistance.BMC Infect Dis. 2019 Mar 29;19(1):293. doi: 10.1186/s12879-019-3829-2. BMC Infect Dis. 2019. PMID: 30925909 Free PMC article.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Critical issues in the clinical management of complicated intra-abdominal infections.Drugs. 2005;65(12):1611-20. doi: 10.2165/00003495-200565120-00002. Drugs. 2005. PMID: 16060697 Review.
Cited by
-
Post-operative abdominal infections: epidemiology, operational definitions, and outcomes.Intensive Care Med. 2020 Feb;46(2):163-172. doi: 10.1007/s00134-019-05841-5. Epub 2019 Nov 7. Intensive Care Med. 2020. PMID: 31701205 Review.
-
Korean Guidelines for Use of Antibiotics for Intra-abdominal Infections in Adults.Infect Chemother. 2022 Dec;54(4):812-853. doi: 10.3947/ic.2022.0156. Infect Chemother. 2022. PMID: 36596690 Free PMC article. Review.
-
Procalcitonin as a marker of Candida species detection by blood culture and polymerase chain reaction in septic patients.BMC Anesthesiol. 2014 Feb 21;14:9. doi: 10.1186/1471-2253-14-9. BMC Anesthesiol. 2014. PMID: 24559080 Free PMC article.
-
Analysis of Bacterial Pathogens Causing Complicating HAP in Patients with Secondary Peritonitis.Antibiotics (Basel). 2023 Mar 6;12(3):527. doi: 10.3390/antibiotics12030527. Antibiotics (Basel). 2023. PMID: 36978393 Free PMC article.
-
Perioperative Antibiotic Prophylaxis and Antimicrobial Therapy of Intra-Abdominal Infections.Viszeralmedizin. 2014 Oct;30(5):310-6. doi: 10.1159/000368582. Epub 2014 Oct 6. Viszeralmedizin. 2014. PMID: 26535044 Free PMC article. Review.
References
-
- Weigelt JA. Empiric treatment options in the management of complicated intra-abdominal infections. Cleve Clin J Med. 2007;74(suppl 4):S29–37. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources